Please assess the completion status of the following clinical trial:

Trial Title: Ulipristal Acetate in Symptomatic Uterine Fibroid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18-48~* Regular cycle of 22-35 days interval and FSH \<=20 mUI/mL.~* \>=1 uterine fibroid of 3\<= d \< 10cm (regardless of location), diagnosed by transvaginal ultrasound.~* Heavy menstrual bleeding (blood loss \>80ml/cycle).~* Uterine size \< 16 weeks of GA on clinical examination.~* Agree to participate in the study.~Exclusion Criteria:~* Previous or current treatment of uterus, cervix, ovarian or breast cancer.~* Previous endometrial ablation or uterine artery embolization.~* Abnormal PAP's smear result within 12 months prior to recruitment.~* Endometrial hyperplasia within 6 months prior to recruitment.~* Uterine polyp \>2cm.~* Ovarian cysts 4cm diagnosed by transvaginal ultrasound.~* Severe anemia (Hb 6 g/dl) or indication for blood transfusion.~* Coagulation disorder indicated for treatment.~* Increased liver enzyme level of twofold or more than normal upper limit.~* Previous use of SPRM.~* Treatment of systemic progestin or intrauterine device or hormonal contraception within 2 months, or use of GnRH analogue within 5 months prior to recruitment.~* Current use of acetylsalicylic acid, mefenamic acid, anticoagulation agents, antifibrinolysis agents, or systemic corticoid

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Ullipristal Acetate (Type: EXPERIMENTAL): Women with symptomatic uterine fibroids will be treated with 5 mg UPA / day in 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).